ÖSTROGENREZEPTOR-ANTAGONISTEN
European patent · EP4310079 · In force
Register entry
- Publication number
- EP4310079
- Application number
- EP22770451
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Mar 14, 2022
- Published
- Jan 24, 2024
- Granted
- Jun 17, 2026
- Protection ends at the latest
- Mar 13, 2042
- Next annual fee due
- Mar 31, 2027
- IPC classes
- C07D 498/04 (2006.01)C07D 519/00 (2006.01)A61P 35/00 (2006.01)A61K 31/4738 (2006.01)
- Priority
- CN 202110277849 15.03.2021
- PCT application
- PCT/CN2022/080680 14.03.2022
- PCT publication
- WO2022/194096 22.09.2022
- Filing language
- Chinese
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Jul 9, 2026
Agent entered
- Representative
- Synergy IP Group AG, Unterer Rheinweg 50, 4057 Basel
Published in Swissreg on 09.07.2026
- Jun 17, 2026
Granted
- Specification status
- Non-published patent application → Granted patent
- Status of protective title
- Initiated → Active
Published in Swissreg on 17.06.2026
Parties
Inventor
YANG, Xuan
Shenzhen, Guangdong 518067, CN
ZHU, Chenggang
Shenzhen, Guangdong 518067, CN
ZHANG, Chaochun
Shenzhen, Guangdong 518067, CN
TALLEY, John Jeffery
Shenzhen, Guangdong 518067, CN
CHEN, Chaole
Shenzhen, Guangdong 518067, CN
BAO, Liming
Shenzhen, Guangdong 518067, CN
MIN, Xiangyan
Shenzhen, Guangdong 518067, CN
XU, Liangliang
Shenzhen, Guangdong 518067, CN
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.